Drugs that contain Fingolimod Lauryl Sulfate
1. List of Tascenso Odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10555902 | HANDA | Stable fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
| US9925138 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
| US10925829 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
Do you want to check out TASCENSO ODT patents from before 2022?
Market Authorisation Date: 23 December, 2021
Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
TASCENSO ODT family patents
7
United States
1
Canada
1
China
1
Australia
1
Japan
1
Taiwan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic